|PHA antivirals by mechanism|
covers both lopinavir and ritonavir since the combination was in trials; recovery trial
32344308 2020. Suggesting Ritonavir against COVID-19/SARS-CoV-2
32473994 2020. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.
32271456 2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
32362644 2020. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
32173576 2020. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
32331982 ä. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
32080993 2020. The Author s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32080992 2020. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32056407 2020. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR
32187464 ä. A Trial of Lopinavir?Ritonavir in Adults Hospitalized with Severe Covid-19
32104907 ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option
32369286 2020. A Trial of Lopinavir-Ritonavir in Covid-19 Reply
32273604 2020. Lopinavir-ritonavir in severe COVID-19
32114746 2020. Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer
32407513 2020. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
32473230 2020. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
32430428 2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
32474026 2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
32422065 2020. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
32385749 2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
32492211 2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
32495917 2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
32475183 2020. Does lopinavir measure up in the treatment of COVID-19?
32369285 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369284 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369283 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369282 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369281 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32443151 2020. Lopinavir pharmacokinetics in COVID-19 patients.
|32453363 2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|
32578156 2020. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
32536150 2020. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
32556272 2020. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
32569450 2020. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.
32598032 2020. Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma.
32530369 2020. Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.
32574332 2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.
32438034 2020. Does lopinavir really inhibit SARS-CoV-2?
32539520 2020. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
32589165 2020. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
32611587 2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.
32616658 2020. BET 1: Lopinavir-ritonavir and COVID-19.
32621621 2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.
32629768 2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.
32641296 2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
32653015 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
32678815 2020. Lopinavir-ritonavir para COVID-19: una revision sistematica viva.
32688374 2020. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
32692462 2020. ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19.
32718719 2020. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.
32740371 2020. A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients.
32740371 2020. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
32759053 2020. A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir.
32765274 2020. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
32767755 2020. Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.
32776298 2020. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
32776534 2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.
32786041 2020. Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir.
32790855 2020. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
32809882 2020. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
32838087 2020. Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with Covid-19.
32855060 2020. Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient.
32856202 2020. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.
32858566 2020. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
32861965 2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
32869007 2020. Lopinavir-ritonavir associated acute kidney injury is not related to crystalluria in critically-ill COVID-19 patients.
32894567 2020. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
32918656 2020. Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.
32942923 2020. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
32953990 2020. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
33031764 2020. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
33042544 2020. Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.
33048175 2020. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.
33048786 2020. Efectos adversos de lopinavir/ritonavir en enfermedad grave por coronavirus (COVID-19).
33075384 2020. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.
33078733 2020. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
33090501 2020. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
33121422 2020. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.
33127507 2020. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
33128482 2020. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
33132915 2020. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.
33136567 2020. Lopinavir-Ritonavir and Liver Involvement in Patients With COVID-19.
33168483 2020. Administracion de lopinavir/ritonavir a traves de sonda de nutricion enteral.
33183365 2020. Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
33187459 2020. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
33206336 2020. Remdesivir versus ritonavir/lopinavir in COVID-19 patients.
33214132 2020. Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy.
33221868 2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
33230045 2020. Plasma Concentrations and Safety of Lopinavir/ritonavir in COVID-19 Patients A Short Communication.
33239282 2020. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
33241457 2020. Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts.
33244631 2020. Reply to the letter to the Editor "Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts".
33245507 2020. Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
33251975 2020. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
33260553 2020. Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.
33262359 2020. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir.
33262433 2020. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.
33307378 2020. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
C7235585 ?. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
C7291608 2020. Lopinavir-Ritonavir-Kombination nicht wirksam.
C7337728 ?. COVID-19 treatment with lopinavir?ritonavir resulting in sick sinus syndrome: a case report.
C7648205 2020. Lopinavir/ritonavir/oseltamivir/warfarin interaction: Increase in the INR and alanine aminotransferase following off label use: 10 case reports.
C7648225 2020. Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports.
C7661803 2020. Lopinavir/ritonavir: Acute liver failure following compassionate use: case report.
C7677433 2020. Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports.
C7692416 2020. Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report.
C7726283 2020. Lopinavir/ritonavir: Worsening of liver injury following off-label use: 7 case reports.
C7728507 2020. Lopinavir/ritonavir: Sick sinus syndrome following off-label use: case report.
C7728521 2020. Lopinavir/ritonavir: Acute kidney injury following off-label use: 8 case reports.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32759267 2020. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
32857301 2020. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
32908681 2020. Possible Retinal Impairment Secondary to Ritonavir Use in SARS-CoV-2 Patients: A Narrative Systematic Review.
33030105 2020. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.
33269470 2020. Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: a physiologically-based pharmacokinetic/pharmacodynamic analysis.
33309661 2021. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
C7651988 ?. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.
32931136 2020. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results.
32933902 2020. Covid-19: RECOVERY trial will evaluate "antiviral antibody cocktail".
33153979 2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.
|32297571 2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|